South Korea · Delayed Price · Currency is KRW EyeGene Statistics
Total Valuation
EyeGene has a market cap or net worth of KRW 49.82 billion. The enterprise value is 24.73 billion.
| Market Cap | 49.82B |
| Enterprise Value | 24.73B |
Important Dates
The last earnings date was Wednesday, August 13, 2025.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
EyeGene has 27.03 million shares outstanding. The number of shares has increased by 10.63% in one year.
| Current Share Class | 27.03M |
| Shares Outstanding | 27.03M |
| Shares Change (YoY) | +10.63% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.43% |
| Owned by Institutions (%) | n/a |
| Float | 19.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.56 |
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.16 |
| EV / Sales | 6.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.77 |
Financial Position
The company has a current ratio of 3.34, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.34 |
| Quick Ratio | 3.20 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.39 |
| Interest Coverage | -15.03 |
Financial Efficiency
Return on equity (ROE) is -22.60% and return on invested capital (ROIC) is -12.40%.
| Return on Equity (ROE) | -22.60% |
| Return on Assets (ROA) | -10.49% |
| Return on Invested Capital (ROIC) | -12.40% |
| Return on Capital Employed (ROCE) | -21.41% |
| Revenue Per Employee | 84.38M |
| Profits Per Employee | -243.68M |
| Employee Count | 47 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 4.22 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.66% in the last 52 weeks. The beta is 1.30, so EyeGene's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | -33.66% |
| 50-Day Moving Average | 2,601.44 |
| 200-Day Moving Average | 2,911.99 |
| Relative Strength Index (RSI) | 19.71 |
| Average Volume (20 Days) | 311,491 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EyeGene had revenue of KRW 3.97 billion and -11.45 billion in losses. Loss per share was -423.84.
| Revenue | 3.97B |
| Gross Profit | 1.17B |
| Operating Income | -10.92B |
| Pretax Income | -11.73B |
| Net Income | -11.45B |
| EBITDA | -8.63B |
| EBIT | -10.92B |
| Loss Per Share | -423.84 |
Balance Sheet
The company has 29.75 billion in cash and 2.57 billion in debt, giving a net cash position of 27.19 billion or 1,005.87 per share.
| Cash & Cash Equivalents | 29.75B |
| Total Debt | 2.57B |
| Net Cash | 27.19B |
| Net Cash Per Share | 1,005.87 |
| Equity (Book Value) | 47.29B |
| Book Value Per Share | 1,671.53 |
| Working Capital | 22.42B |
Cash Flow
In the last 12 months, operating cash flow was -5.88 billion and capital expenditures -678.29 million, giving a free cash flow of -6.56 billion.
| Operating Cash Flow | -5.88B |
| Capital Expenditures | -678.29M |
| Free Cash Flow | -6.56B |
| FCF Per Share | -242.58 |
Margins
Gross margin is 29.52%, with operating and profit margins of -275.40% and -288.77%.
| Gross Margin | 29.52% |
| Operating Margin | -275.40% |
| Pretax Margin | -295.74% |
| Profit Margin | -288.77% |
| EBITDA Margin | -217.72% |
| EBIT Margin | -275.40% |
| FCF Margin | n/a |
Dividends & Yields
EyeGene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.63% |
| Shareholder Yield | -10.63% |
| Earnings Yield | -22.99% |
| FCF Yield | -13.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 28, 2021. It was a forward split with a ratio of 1.2.
| Last Split Date | Jun 28, 2021 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
EyeGene has an Altman Z-Score of -0.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.27 |
| Piotroski F-Score | 2 |